The overall dynamics of the global hemato oncology testing market are consistently evolving with technological advancements in the healthcare and medical domain. There has been a considerable growth in the occurrence of hematologic cancer across the globe. This has led to people being more aware of the disease and its treatment options. These factors are key in driving the growth of the global hemato oncology testing market in recent years.
The market players are investing heavily in the research and development activities to develop new treatment methods and tests. This is expected to fuel the competition among the market players over the course of the given forecast period of 2018 to 2028. Key players in the market are adopting aggressive marketing tactics such as joint ventures and collaborations to bolster their business profiles.
Get Sample Copy of this Report @
The overall vendor landscape of the global hemato oncology testing market is highly competitive and fragmented due to the presence of several key companies. Of the numerous companies plying their trade in the global market, Abbott Laboratories and F. Hoffmann-La Roche have emerged to be the industry leaders. With a large array of diagnostic tests for identifying hemato oncology cancers such as leukemia, myeloma, and lymphoma, Roche has been recently been at the top position. The company is now working on strengthening its distribution channels in order to maintain its current position in the market.
Some of the key developments in the global hemato oncology testing market are given below:
• Recently, Invivoscribe announced that it has collaborated with the American University of Beirut Medical Center to build and design a new treatment center in the Middle East. The research center will primarily focus on advanced research on treatment and tests for hemato oncology cancers.
• In 2018, Abbott Laboratories received approval from FDA for its Abbott RealTime IDH1 kit. The objective behind the kit was to bolster its brand value with the help of new products.
Read Comprehensive Overview of Report @